Literature DB >> 12065335

Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis.

Gavin R Graff1, Jane L Burns.   

Abstract

STUDY
OBJECTIVES: To identify factors predisposing cystic fibrosis (CF) patients to Stenotrophomonas maltophilia infection and to determine whether coinfection with S maltophilia affects the clinical response to therapy with tobramycin solution for inhalation (TSI), 300 mg bid.
DESIGN: Retrospective review of data collected from two identical, 6-month, randomized, placebo-controlled trials.
SETTING: Sixty-nine CF centers in the United States.
INTERVENTIONS: Active drug administration of 300 mg TSI. PATIENTS: Five hundred twenty CF patients with chronic Pseudomonas aeruginosa endobronchial infections. MEASUREMENTS AND
RESULTS: A logistic regression analysis identified factors contributing to increased S maltophilia isolation frequency. In this multivariate analysis, the only significant predictors of S maltophilia isolation during the last month of the trial were the concomitant use of oral quinolones (primarily ciprofloxacin; p = 0.0015) and S maltophilia isolation prior to treatment (p < 0.0001). Treatment group, gender, age, use of systemic or inhaled steroids, use of oral sulfonamide, IV cephalosporins, or penicillin antibiotics, baseline FEV(1) percent predicted, and pretreatment Aspergillus isolation were not significant predictors of subsequent S maltophilia infection. In addition, S maltophilia-positive culture frequency was compared to the change in pulmonary function. Patients who either never had culture results positive for S maltophilia or who were positive at <25% of observations had greater clinical response to TSI at the final study visit compared to patients who were positive at > or = 25% of observations.
CONCLUSIONS: TSI therapy did not result in a greater risk for isolation of S maltophilia than standard care alone. In contrast, oral quinolone antibiotic use during the trial was associated with a 2.7-fold increased risk of having a culture positive for S maltophilia (p = 0.0015). The use of TSI to suppress P aeruginosa resulted in improved lung function, regardless of S maltophilia culture frequency. However, improvement was not as great among patients who were persistently coinfected with S maltophilia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065335     DOI: 10.1378/chest.121.6.1754

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  17 in total

Review 1.  Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.

Authors:  Melissa B Miller; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

2.  Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.

Authors:  Valerie J Waters; Marisa I Gómez; Grace Soong; Sunil Amin; Robert K Ernst; Alice Prince
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

3.  Identification and management of unusual pathogens in cystic fibrosis.

Authors:  J Stuart Elborn
Journal:  J R Soc Med       Date:  2008-07       Impact factor: 5.344

Review 4.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

5.  Stenotrophomonas maltophilia Differential Gene Expression in Synthetic Cystic Fibrosis Sputum Reveals Shared and Cystic Fibrosis Strain-Specific Responses to the Sputum Environment.

Authors:  Graham G Willsey; Korin Eckstrom; Annette E LaBauve; Lauren A Hinkel; Kristin Schutz; Robert J Meagher; John J LiPuma; Matthew J Wargo
Journal:  J Bacteriol       Date:  2019-07-10       Impact factor: 3.490

6.  Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis.

Authors:  Nicole Ritz; Roland A Ammann; Carmen Casaulta Aebischer; Franziska Schoeni-Affolter; Martin H Schoeni
Journal:  Eur J Pediatr       Date:  2005-05-31       Impact factor: 3.183

Review 7.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

Review 8.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

9.  Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Authors:  Arianna Pompilio; Valentina Crocetta; Pamela Confalone; Mauro Nicoletti; Andrea Petrucca; Simone Guarnieri; Ersilia Fiscarelli; Vincenzo Savini; Raffaele Piccolomini; Giovanni Di Bonaventura
Journal:  BMC Microbiol       Date:  2010-04-07       Impact factor: 3.605

10.  Emerging pathogens in cystic fibrosis: ten years of follow-up in a cohort of patients.

Authors:  L Spicuzza; C Sciuto; G Vitaliti; G Di Dio; S Leonardi; M La Rosa
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-08-29       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.